MetaVia Inc. (MTVA) Stock Score, Valuation & Financial Research

MetaVia Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MTVA

MetaVia Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.47. These figures are a research snapshot, not a buy or sell recommendation.

What MetaVia Inc. does

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

MetaVia Inc. is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and debt financing to fund the research and development of novel pharmaceutical candidates for cardiometabolic diseases.

Products and services

  • The company is developing a pipeline of drug candidates, primarily focusing on DA-1241 (vanoglipel) and DA-1726, which are intended for the treatment of cardiometabolic conditions.

Brands and product families

  • DA-1241 (vanoglipel) — Lead clinical-stage drug candidate for cardiometabolic diseases. Source
  • DA-1726 — Clinical-stage drug candidate in the company's pipeline. Source

Suppliers, materials and equipment

  • Dong-A ST — Contract manufacturer for clinical quantities of vanoglipel (DA-1241) and DA-1726. Source

Business relationships and partnerships

  • Dong-A ST — The company maintains a license agreement and a shared services agreement with Dong-A ST for the manufacturing of clinical quantities of its drug candidates. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting cardiometabolic diseases Source

Business risks and research considerations

  • History of operating losses and dependence on external financing Source
  • Reliance on third-party manufacturers like Dong-A ST Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MTVA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.47
Market capitalization:
9.68M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -14.45M
Free cash flow:
USD -15.7M
Cash:
USD 12.63M
Total debt:
USD 177K
EPS:
USD -4.07

What stands out

  • Free cash flow is USD -15.7M, negative for the stored period.
  • The balance sheet shows USD 12.63M of cash versus USD 177K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 12.46M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MTVA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MTVA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MTVA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MTVA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MTVA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research MTVA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.